Home Based Infusions for Ocrelizumab

The safety of home ocrelizumab infusion will be assessed by monitoring for infusion reactions and adverse events, and comparing proportions/rates to existing studies. Patient reported outcomes (PROs) will compare pre to post infusion.

Inclusion criteria

• Current active patient of Rocky Mountain MS Center at the time of final study consent.
• Between 18-55 years of age at the time of final study consent.
• Diagnosis of primary progressive or relapsing MS as defined by the 2017 McDonald criteria.19
• Has at minimum completed their first 600 mg dose of ocrelizumab.
• Is physically residing in the Denver metro, Fort Collins or Colorado Springs area at the time of final study consent.
• Has a Patient Determined Disease Steps (PDDS) between 0 to 6.5 20
• Can complete patient reported outcomes developed and validated as English written scales.
• Must be able and willing to give meaningful, informed consent via electronic signature prior to participation in the study, in accordance with local and FDA regulatory requirements.
• Whose treating neurologist at the RMMSC feels that continuing ocrelizumab s medically appropriate based on at the time of final study consent.

Exclusion criteria

• Not pregnant, intentions to get pregnant or lactating at the time of final study consent and on the day of infusion.
• Has previously not participated in the SaROD trial at the RMMSC site.
• Any of the following abnormal laboratory results as processed by a University of Colorado Hospital laboratory site and deemed clinically inappropriate to proceed with a home infusion by the treating neurologist at RMMSC.